Physician profile
Kenneth Ferrera
NPI 1164899241
$7,179.17
in general payments reported to CMS, 2019-2025
24 companies · $2,488 in 2025
The $2,488 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $383 · 2022: $862 · 2023: $1,053 · 2024: $2,394 · 2025: $2,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,531 · Education: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,531.22 |
| Education | $403.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,398.51 | 2022-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,008.35 | 2021-2025 | Tremfya |
| Abbvie INC. | $845.32 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $553.18 | 2021-2025 | Dupixent |
| Genzyme Corporation | $505.58 | 2022-2025 | |
| Leo Pharma INC. | $419.35 | 2021-2025 | Anzupgo, Adbry |
| E.R. Squibb & Sons, L.L.C. | $407.98 | 2022-2025 | Sotyktu |
| Organon LLC | $322.89 | 2024-2025 | Vtama |
| Dermavant Sciences, INC. | $263.70 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $262.93 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $253.21 | 2022-2025 | |
| Lilly USA, LLC | $199.83 | 2022-2025 | Taltz, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.56 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Pfizer INC. | $113.46 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $108.98 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $68.73 | 2024-2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $58.66 | 2024-2025 | Ycanth |
| Mayne Pharma Commercial LLC | $54.84 | 2021-2023 | |
| Almirall LLC | $52.90 | 2022 | |
| Galderma Laboratories, L.P. | $32.11 | 2022-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.20 | 2024 | Spevigo |
| Amgen INC. | $29.03 | 2025 | Otezla |
| Strata Skin Sciences, INC. | $19.91 | 2025 | Xtrac |
| Arcutis Biotherapeutics, INC. | $18.96 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Ferrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.